Jun 22, 2023 8:05am EDT Inhibikase Therapeutics Announces Selection of the Bioequivalent Dose of IkT-001Pro and Provides Update on the '501' Bioequivalence Study
Jun 21, 2023 8:05am EDT Inhibikase Therapeutics Initiates Medical and Patient Awareness Campaign for its Phase 2 '201' Trial Evaluating IkT-148009 in Parkinson's Disease
May 16, 2023 7:45am EDT Inhibikase Therapeutics Announces Dosing of First Patient in its Phase 2 '201' Clinical Trial of IkT-148009 to Treat Parkinson's Disease
May 15, 2023 8:30am EDT Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity
May 08, 2023 8:05am EDT Inhibikase Therapeutics to Report First Quarter Financial Results on May 15, 2023
May 04, 2023 8:05am EDT Inhibikase Therapeutics to Present at the Sidoti Micro-Cap Virtual Conference
Apr 26, 2023 8:00am EDT Inhibikase Therapeutics Provides Safety and Functional Update on its Phase 1/1b 101 Trial and its Phase 2 IkT-148009 201 Trial in Parkinson's Disease
Mar 31, 2023 8:22am EDT Inhibikase Therapeutics Reports Full Year 2022 Financial Results and Highlights Recent Period Activity